A consultant, cancer specialist leading cancer treatment services at the Primrose Oncology & Research Unit, Bedford since 1996. Professor Robert Thomas also leads the prostate brachytherapy program and supervises Radiotherapy at Addenbrooke’s Hospital, Cambridge University NHS Trust and is a visiting professor at Cranfield University. Main tumour site interests include Breast, Urology and Colorectal cancer. (Publication list)

Qualifying in 1984 at 22 years, after training as a general physician, formal oncology training in mainstream cancer care took place at the Royal Marsden, Royal Free, Mount Vernon and Middlesex Hospitals London.

Other roles include being deputy editor of the British Journal of Cancer Management and editor of the the medical journal "Focus on cancer medicine" and editor of cancernet.co.uk. and keep-healthy.com. Medical student teacher at Cambridge University and lecturer at Cranfield University.

Research training 1992-4: The National Hospital & Institute of Neurology , Queen Square .  Institute of Cancer Research, Dukes University North Carolina, USA. This full time research post  investigated firstly the role of intralesional radioimmunotherapy in patients with recurrent high grade glioma. Secondly, a laboratory project evaluating the distribution and dosimetric attributes of intralesional radiolabelled MAb in experimental animal tumours. Thirdly, a computer and physics based project studying the impact of 3-D multimodal  image registration for stereotactic radiotherapy and surgery.  

Current research interests Academic interests have now turned to methods which improve patient’s understanding of their disease and treatment options. This research has produced a number of practical information tools ranging from bespoke patient booklets, leaflets and 6 video films. The methodology for this research is also now being taught to colleagues and students internationally in formal teaching programs, medical conferences and invited lectures. More recently research has focused on how lifestyle can improve quality of life and disease outcome following a diagnosis of cancer. As well as a number of practical lifestyle strategies for patients, his team have designed and are conducting two of the UK largest quality of life and lifestyle studies in patients with breast and prostate cancer.

Awards & prizes

• Roche MD Anderson prize for clinical research 1994.

• The Northwest travelling fellowship 1995.

• BUPA Foundation communication prize merit 1999

• BUPA foundation communication sponsorship award winner 1999

• BMA book prize – winner 1999,  

• BMA video prize – merit 2000

• Hospital doctor magazine innovation category finalist nomination 1999

• Hospital doctor magazine innovation category – winner 2000

• Hospital doctor magazine - Doctor of the year 2000

• NHS communication research prize – winner 2001

• British Oncology Association - Oncologist of the year 2007

 Management experience 

• Founder & chairman of the Bedford Information for Patients Research Group
• Founder & chairman of the Addenbrooke’s Information for Patients Research Group
• Regional (network) editorial board & medical director for patient information.
• Member of the Research & Development Meeting Addenbrooke’s.
• Member of the Radiotherapy quality steering Group Addenbrooke’s
• Member of the Chemotherapy quality Steering Group Addenbrooke’s
• Network Drugs & therapeutic and Urology committees
• Bedford Breast, GI & Urology MTD

• Editorial member of the National Institute for Clinical Excellence panel for supportive care.

• Oncology lead of the DoH working party for Complementary Medicines,

•  Executive member of the National patient advisory group on clinical trials

• Editor & producer of cancer BACUP’s patient information films.

• Adviser & editorial member of the “Supportive & Palliative care” section of the NHS Cancer plan 1997-9.

 Invited lectures

• The Royal Free Hospital (Neuro-Oncology), July '93 & September '95.

• The Middlesex Hospital (Neuro-Oncology), September '93.

• The Institute of Psychiatry (Radiobiology) January '94.

• The National Hospital for Neurology (Neuro-Oncology), March '94.

• St Lukes Hospital, Guilford (High dose chemotherapy), October '95.

• Royal College of Radiologist annual conference 1994, Warwich.  (Neuro-Oncology), '94.

• The International Science festival, Edinburgh . April '95.

• Cancer Update (Seminoma). RMH,  July '95.

• Cambridge University – Clinical research – How to succeed 1997

• Breast cancer symposium – Cholester 1998

• Cancer Bacup – Improving in formation for patients in practice 1998

• Edingburgh University / Western General – Fatigue and Chemotherapy 1998

• Cardiff , Birmingham & Manchester – Anaemia and fatigue 1998

• Royal College of Physicians – Anaemia and fatigue 1999

• Royal College of Pathologist – Cost effectiveness of Gcsf in clinical practice 1999

• Marie Curie – National symposium on information for Patients 1999

• Mount vernon , UK National symposium on information for Patients Jan 2002

• Breast cancer symposium – Cost effectiveness of Adjuvant Aromatase inhibitors 2005

International:

• Memorial Sloane Kettering Hospital , New York , USA , 1994

• Duke University Medical Centre, North Carolina   February 1996.

• Amgen symposium Atlanta   USA (ASCO) 1999

• Melbourne , Australia (COSA) Treating anaemia in oncology – 1999

• Ischia , Italy . International symposium on information for Patients Nov 200

• Morelia , Mexican Annual Cancer Conference  - Optimising raltitrexed use Nov 2001

• Orlando USA – Novartis symposium (ASCO) – Patient choice and AI’s May 2002

• Sao Paulo , Brazil – Novartis symposium – Qol issues and AI’s June 2002

• Athens – Novartis symposium – Qol & choice in breast cancer management 2004

• Mexico city - Opening of the national patient information program - July 2007

Original clinical research – Lead investigator (first author)

What size chest tube for pleural effusions?   Dr Robert J Thomas, Dr S M Sagar. British Journal of Hospital Medicine  (l990). Vol 43. p.53.  

An analysis of surveillance for stage one  combined teratoma/seminoma  of the testis. Thomas R, Dearnaley D,  Horwich A.  British Journal of Cancer. 1996, 74: 59-63.

Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma.  R J Thomas,  N James, D  Guerro, S Asley , A Gregor, M Brada. Radiotherapy & Oncology (1995). Vol,.33, pp.113-116.

Speech and language disorders in patients with high grade gliomas and its influence on survival.    R. J. Thomas,  M O'Conner,  S Ashley,  M Brada.   Journal of  Neuro-Oncology (1995). Vol.23: p.265-270.

Pneumothorax and palliative pleural aspiration - an audit of technique.Dr Robert J Thomas, Dr J Maher.  Palliative Medicine (1993): 7: pp 67-71.

Metastatic Parathyroid Carcinoma.  Dr Robert J Thomas, Dr A Cassoni. Journal of the Royal Society of Medicine (1992). 85(3) 92;182.

Modifying the Barthel performance index score for use with patients with brain tumours. R.J.Thomas D Guerrero, F Hines,  M Brada. European Journal of Cancer Care (1995) Vol.4, pp. 63-68.

Modifying the Barthel index for use in patients with brain tumours - an update.  R Thomas. European journal of cancer care February 1997, 6:2

Distribution kinetics of radiolabelled monoclonal antibodies in experimental tumours following interstitial and systemic administration.  Dr R J Thomas, P Carnochan, M Brada - Radioactive isotopes in Nuclear Medicine research. 1994  

Patients preferences for video cassette recorded information.  Effect of age, sex and ethnic group.Thomas R, Deary A, Kaminski E,  Diane Stockton (statistician)³,  N De Zeeuw. The European Journal of Cancer Care. Vol –8 Jan, 1999

Patients preferences for video directed information. Effects of age, sex and ethnic group. R Thomas, D Stockton, European Journal of cancer Care 1999;8: 83-86.

Forewarned is forearmed – benefits of preparatory information on video casette for patients receiving chemotherapy and radiotherapy- a randomised trial. Thomas R, Daly M, Perryman B, Stockton D EJC issue 36 (2000) 1536-1543.

Lessons Learnt from Raltitrexed – Quality Assurance, Patient Education and Intensive Supportive Drugs to Optimize Tolerability.  R.J. Thomas, M. Williams, J. Garcia-Vargas Clinical Oncology (2003) 00:1-6.

Examining quality of life issues in relation to endocrine therapy for breast cancer.Robert Thomas. American Journal of Clinical Oncology 2003. Vol. 26, No. 4, pp S40-S44

Measuring information strategies in oncology – developing an information satisfaction questionnaire. Thomas R, Kaminski E, Stanton E and Williams M. European Journal of Cancer Care, 2004, 13, 65-70.

To what extent does neutropenia impact on the ability to deliver planned chemotherapy in lymphoma? – The results of a UK neutropenia audit J Sweetenhama*; B Hancockb; R Pettengellc; A Pagliucad; R Thomase; P Hoskinf; A McMillang; M Joynerh; D Spooneri.

Giving patients a choice improves quality of life: A multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. R. Thomas, S. Godward, A. Makris, D. Bloomfield, A.M. Moody, M. Williams. Clinical Oncology (2004) 16: 485-491.

Dietary advice combined with a salicylate mineral and vitamin supplement (CV247) has some tumour static properties - a phase II study. R Thomas, M Blades, M Williams and S Godward . Nutrition & Food Science 2005, Volume 35 Issue 6, 436- 451

Editorials:

Endometrial carcinoma - Adjuvant locoregional  therapy.   Dr Robert  J Thomas,  Dr Peter Blake  [Editorial].  Clinical Oncology. 1996 8: 140-146.

Patient Information materials in Oncology: Are they needed and do they work? Thomas R, and H Thorton. Clinical Oncology 1999;11: 225-231  

How to deal with the complexities of patient consent? Robert Thomas.  Pulse Clinical pp42-43 December 2003.The changing face of informed consent. R Thomas. British Journal of Cancer Management. Summer 2004 Vol. 1 No. 1.

What are the costs of not using rhEPO to treat anaemia in cancer. Robert Thomas. Focus on anaemia in cancer. 2002, Vol 3, issue 2, pp52-53.

NICE guidance on supportive and palliative care – Implications for Oncology Teams. Dr R Thomas and  Professor Alison Richardson. Clinical Oncology (2004) 16: 420-424.

The NICE guidance on supportive and palliative care. Dr Robert Thomas and Professor Alison Richardson. British Journal of Cancer Management 2004; Vol. 1 No. 3.

Restructuring supportive care – Affect on oncology practice. R Thomas. British Journal of Cancer Management. Vol.2 No.4 April 2005.  

Anaemia fatigue and Epoeitin in Oncology R Thomas. British Journal of Cancer Management. Vol.2 April No. 4, 2005.

Complemenatry and alternative medicine evidence online for cancer. J Richardson, K Pilkington and R Thomas. BJCM 2005, vol.2, no.2, pp10-12.

Letters

 Writing medical Papers [letter].  Dr Robert J Thomas. Journal of  The Royal Society of Medicine August 1993

Evidenced based patient information - Local policies would be better than a national strategy [letter]. 1999, British Medical Journal, vol 318. page 462.

Further differential diagnosis of hilar masses  [Letter].  Dr Robert J Thomas. The British Journal of Radiology  (1992).  Vol.65,  No.774, p.553.   

Case reports with literature review

Mistaken Hilar Mass.   Dr Robert J Thomas, Dr G Duchesne.  The British Journal of Radiology (1991).  Vol.64, No.766, p.977-978.  

The Tin-Tack sign in post irradiation scalp skin scales.   Dr Robert  J Thomas, Dr Neil Smith,  Dr Margaret Spittle.  British Journal of Dermatology (1992). Vol 126/1: 90

PET saves man. Robert Thomas, Madeleine Williams & Sally Old. British Journal of Cancer Management. Summer 2004 Vol. 1 No. 1, p22-23

Bevacizumab saves the day. R Thomas, Sanjay Raj, Ahmed Eldin. 2005. BJCM. Vol.2, number 2. p20-21.

Original clinical research, (not first aurthor)

Olfactory sensations produced by high-energy photon irradiation of the olfactory receptor mucosa in humans.   Stephen Sagar, Robert J Thomas, L. Loverock, Margaret Spittle.

International Journal Radiation Oncology Biology Physics  (1990). Vol 20, pp 771-776.Dosimetry of intralesional 131I monoclonal antibody therapy in patients with recurrent high grade glioma.   S. Chittenden,  R. Thomas, G. Flux, T. Smith, M. Brada, M. Flower, R. Ott. Jan 1995. (1). pp. 270-274.

Mathematical modelling of 3D intracranial radioisotope dose distribution. G Flux, R Thomas, R Ott, Eur. J. Nuclear Medicine. published July 1997.

The verbally administered barthel index in patients with glioma. Dr L Brazil , Dr R Thomas, Dr M Brada.  Radiation and Oncology, July 1995.  

The Role and Activity of an Italian Volunteer Organisation providing Information and Emotional Support for Patients with Cancer.  F. De lorenzo, c. Paglia  i. Duce and U. Tirelli, R. Thomas,. G. Vecchio.  Dipartimento di Biologia e Patologia Cellulare e Molecolare L. Califano, Universita Federico Napoli. Nov '98. Health communications  1999.

An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole.  C. Rose, O. Vtoraya, A. Pluzanska, N. Davidson, M. Gershanovich, R. Thomas, S. Johnson, et al. European Journal of Cancer 39 (2003) 2318-2327.  

Complementary and Alternative Medicine Evidence On-Line (CAMEOL) For Cancer J Richardson,  K Pilkington & Robert Thomas. Bristish Journal of Cancer Management accepted for december 2005, Volume 5.

Aloe Vera for preventing radiation-induced skin reaction: A systemic literature review. J Richardson, J Smith, M McIntyre, R Thomas, K Pilkington. Clinical Oncology. 2005, 17:478-484.

 Online Journals:

 Black Cohosh for menopausal symptoms in women with breast cancer: A systematic literature review. Joanna Smith, Janet Richardson, Michael McIntyre, Rob Thomas, Karen Pilkington. http://rccm-host.wmin.ac.uk/cameo/

Research pending:

 Lymphoma – audit of UK chemotherapy practice – Professor Bob Lennard and Dr Robert Thomas

Breast cancer –audit of UK chemotherapy practice – Dr Ruth Pentigall & Dr Robert Thomas

Book chapters:

Multimodal Image registration for radioimmunotherapy   R. Thomas, G. Flux,  M. Brada,

R Ott. In  Radioactive isotopes in Nuclear Medicine and research. Jan 1995. p175-182  

Intralesional radiolabelled MAb in experimental tumour. R Thomas, P Carnochan, S Eccles, M Brada. For;  Radioactive isotopes in Nuclear Medicine and research. Jan 1999. 

Lifestyle after cancer - Oxford Handbook of Oncology 2008

The Internet and Cancer - Oxford Handbook of Oncology 2008

Book reviews:

'Modern developments in chemotherapy' A review for Haematology - August 1999

 A combined approach to cancer management. A review for BOA magazine 2000

 Books:

 Simple tips for a Happy Family - Reducing arguments. Professor Robert Thomas 2008 Available from www.lulu.com/content/1847981.

Talks and abstracts: 

Olfactory sensations in Radiotherapy. Robert J Thomas, S Sagar , M Spittle.  BIR Annual conference. Harrogate 1990. Abstract, British Journal of Radiology, Sept 1990.   

Distal Muscle Involvement in a new category of Muscular Dystrophy. R  Thomas,  R Goodwin-Austen. The Midlands Annual Neurological Conference.  Wolverhampton ,  June'86. Conference proceedings.  

Diffusion characteristics of intralesionally administered 131I monoclonal antibody in patients with recurrent high grade glioma. R J Thomas, M Brada, P Carnochan G. Flux, N Kitchen, D Bigner, M Zalutsky. 10th International conference on Brain Tumour research. Voss , Norway .  J of Neuro-Oncology. 1993. vol.15 suppl. pp.28.  

Localisation of uptake in radioimmunotherapy using a stereotactic head frame. R J Thomas, G Flux, M Brada. Royal College of Radiologist annual conference 1993, Warwich.  Clinical Oncology October 1993.

Image registration with the aid of a stereotactic head frame for radioimmunotherapeutic studies. British journal of Neurosurgery. (British Neuro-oncology group conference June 1993 ) RJ Thomas, G Flux, S Chittenden , B Cronin,  R Ott,  M Brada.  British Journal of Neurosurgery. Dec 1993.

 Dosimetry of intralesional 131I monoclonal antibody therapy in patients with recurrent high grade glioma. S. Chittenden, R. Thomas, G. Flux, T. Smith, M. Brada, M. Flower, R. Ott. European Journal of Nuclear Medicine. Jan. 1994, Vol 21. p3

Multimodal Image registration for radioimmunotherapy - Surface landmark and frame based correlation in patients with recurrent high grade glioma. R. Thomas S, Chittenden,G. Flux, T. Smith, M. Brada,  R. Ott. European J of Nuc Med. Jan 1994. Vol.21, pp7.

 Speech and language disorders in patients with high grade gliomas and its influence on survival. R Thomas, M O'Conner, S Asley , M Brada. (First congress of the European Association for Neuro-Oncology).  1994. Journal of Neuro-Oncology Vol.21, No.1. p.22.

 Speech and language disorders in patients with high grade gliomas and its influence on survival. (British Neuro-oncology group conference June 1994 ).  R Thomas, M O'Conner, S Asley , M Brada. British Journal of Neurosurgery. Dec1994.

Verbally administered Barthel Index as functional assessment in brain tumour patients. R Thomas,  M Brada.  (Brit. Neuro-oncology  group conference ).  B J Neurosurg. Dec'94.

 Intralesional 131I-labelled Mab therapy in patients with recurrent high grade glioma. R. Thomas , S Chittenden ,  G. Flux, R. Ott,  M. Brada.  (British Neuro-oncology group conference July1994)  British Journal of  Neurosurgery. Dec 1995.

 Intralesional 131I-labelled Mab therapy in patients with recurrent high grade glioma. R. Thomas , S Chittenden ,  G. Flux, R. Ott,  M. Brada.  (First congress of the European Association for Neuro-Oncology).  1994. Journal of Neuro-Oncology Vol.21, No.1. p.68.

 Acute morbidity following catheter implantation for interstitial brachytherapy and immunotherapy for glioma. P Doshi, R Thomas, R Beaney, D Thomas. (British Neuro-oncology group conference 1994)  British Journal  of  Neurosurgery. Dec 1994.

 Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma.  R Thomas, N James, A Gregor, M Brada.. (1st congress of the European Ass. for Neuro-Oncology).  1994.  Journal of Neuro-Oncology Vol.21, No.1. p.45.

 Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. N James, R Thomas, D  Guerro, S Asley , A Gregor, M Brada. ( BOA 1994). British Journal of Cancer July 1994, Vol. 70. Supplement XX11.  

Intralesional 131-I labelled Mab therapy in patients with recurrent high grade gliomas. (BOA 1994). Thomas R, Flux G, Chittenden S, Hall A, Kitchen N, Thomas DGT, Bigner D, Zalutsky, Brada M.  British Journal of Cancer July 1994, Vol. 70. Supplement XX11.

 38)Verbally administered Barthel Index as functional assessment in brain tumour patients. R Thomas, L Brazil,  M Brada (The first congress of the European association for Neuro-oncology April 1994). 21, (1), p.71.

 Monoclonal antibodies in Neuro-Oncology - a review.  R Thomas. Royal College of Radiologist annual conference 1994, Warwich. Abstract. Clinical Oncology October 1994.

 Multimodal image registration for radioimmunotherapy. Surface Landmark and frame based correlation in patients undergoing intralesional 131-I MAb therapy for recurrent high grade glioma. (BOA 1994) Thomas R, Flux G, Chittenden C, Ott B, Brada M.  British Journal of Cancer July 1994, Vol. 70. Supplement XX11.

 The use of multimodality imaging to monitor intralesional therapy. G. Flux,  R. Thomas,  S.Chittenden,  T. Smith, M. Brada, M. Flower, R. Ott.  ( W.F.N.M.B Sydney 1994)  European Journal of Nuclear Medicine. September 1994.

 Stage one mixed teratoma/seminoma - outcome and patterns of failure following surveillance.  Thomas R ,  Dearnaley D  and  Horwich A. (BOA 1995).  British Journal of Cancer. July 1995.

 Distribution kinetics of radiolabelled MAbs in experimental tumours following interstitial and systemic administration. Dr R J Thomas, P Carnochan, M Brada. (ECCO 1995) Radiotherapy and Oncology. Nov. 1995.

 Lymphography - its role in the radiotherapy planning of carcinoma of the cervix. Thomas R, Wilkins M, Blake P. ( Conference: Brachytherapy and external beam radiotherapy for carcinoma of the cervix). February 1996. British Journal of Radiology.

 Carcinoma of the cervix. the role of lymphography in individualising the planning target volume. (BOA 1996). R Thomas, M Wilkins, N Hinds, P Blake. For British Journal of Radiology; 69:579

 Patients attitudes towards video directed information - A multicentre study.   Deary A, Kaminski E, Thomas R. The European Journal of Cancer. (ECCO) 1997. Vol. 33, Supplement 8, 1389.

 Do patient's want the same information as the GP?  Kaminski E, Deary A, Thomas R. The European Journal of Cancer. (ECCO) 1997. Vol. 33, Supplement 8, 1391.

 Patient preferences for and satisfaction to a breast care nurses specialist. Shingler G, Smith S, Thomas R. European Journal of Cancer. (ECCO) 1997. Vol. 33, Supplement 8, 1397.

 Cancer patient education and information: Development of a new structured information package. DeZeeuz N, Bulusu R, Thomas R.  EJC. (ECCO) 1997. Vol. 33, Sup 8, 1400.

 Patients attitudes towards an individualised filofax information system. Kaminski E, DeZeeuz N, Balusu R, Thomas R.  EJC. (ECCO) 1997. Vol. 33, Sup 8, 1401.

 Where do patients seek additional information after a diagnosis of cancer - A multicenre survey. Shingler G, Bulusu R, Thomas R. EJC. (ECCO) 1997. Vol. 33, Sup8, 1426.

 Comparison of intralesional and systemically administered radiolabelled MAb in experimental tumours. R Thomas, P Carnochan, S Eccles, M Brada. E J Nuclear Med. Sup.4. Jan 1998.

 Video directed information - Patient satisfaction following a diagnosis of cancer. Deary A, Malone L, Jessop L, Akass C, Thomas R. Annuls of Oncology (ESM0) Volume 9, Supplement 4, pp 143.

 Anxiety and Depression - Effect on patients preferences for information following a diagnosis of cancer. Thomas R, Brown C, Dalton L, Welton S, Stockton D. Ann of Onc (ESM0) Vol 9, Sup 4, pp 141.

 Treatment of platinum-induced anaemia eith epoetin alpha: Attitudes of community and hospital based nursing staff.  A Deary and R Thomas. The European J. of  Cancer. Vol.35. Suppl.4. p.30  (ab. 92).

 Why Oncologist should provide a web site for their patients. L Dalton and R Thomas. The European Journal of  Cancer. Vol.35. Suppl.4. p.46  (ab. 164).

 Preparatory information on video cassette significantly reduces treatment associated anxiety and depression - A randomised multicentre trial. R Thomas, M Daly, F Delorenzo The European Journal of  Cancer. Vol.35. Suppl.4. p.275  (ab. 1101).

 Thomas R, Daly M, Dalton L, Perryman B, Stockton D. Preparatory information on video significantly improves treatment associated anxiety, depression and satisfaction - a multicentre study. JCO 1999;Supp 8 (ASCO):1570  

Optimising the side effects of raltitrexed with appropriate supportive drugs: a prospective community hospital study. Thomas R, Bulusu R. EJC March 2001 vol 37, supp.2 pp119.

 Lyphpoma Chemotherapy – an audit of neutrpenia, dose intensity, and gcsf use in the UK . R Thomas, J.Sweetman, P Hoskins. EJC March 2001 vol 37, supp.2 pp119  

Adjuvant breast cancer Chemotherapy – an audit of neutrpenia, dose intensity, and gcsf use in the UK . R Thomas and R Leonard. EJC March 2001 vol 37, supp.2 pp61  

Developing and evaluating a regional patient information strategy.  R Thomas, C.Lockery. EJC March 2001 vol 37, supp.2 pp 62  

Measuring resposes to received information – development of a patient satisfaction questionnaire. Kaminski E, Thomas R EJC (1396) vol 37 supplement 6 October 2001

 Early intervention with Epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy.ESMO 2002

 Early intervention with Epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy.’  H Thomas, R Thomas, K McAdam, J Joffe, E Sugden, S Awwad, LT Tan, P Murray, N Bailey, A Branson. S ESMO , Nice 2002.

What are the costs of not using rhEPO to treat anaemia in cancer?Robert Thomas  Focus on Anaemia in cancer. Vol 3, Issue 2, 2002, Supported by Roche.

 Empowering patients to make informed treatment decisions based on tolerability, quality of life and patients preference. A compariston of letrozole and anastrazole in a multi-centre, randomised, single blind cross over study. R. Thomas, A. Makris, D. Bloomfield , S. 3^rd European Breast Cancer Conference, Barcelona . 2002. EJC. 38, sup 3, pg S83, No. 171

 Empowering patients to make informed treatment decisions based on tolerability, quality of life and patients preference. David J Bloomfield, Robert Thomas, Andreas Makris, Sara Godward and Margaret Moody. 27^th ESMO Congress, Nice, France. Annals of Oncololgy, vol. 13, 2002, supplement 5, pg 32. No. 114PD

 Preliminary phase II results of the salicylate rich formula CV247 in patients with malignant disease.  Robert James Thomas, Sara Godward, Madeleine M. Williams, Wassif F. Wassif.Abstract Book of the 27^th ESMO Congress, Supplement 5, Pg 30.

 Preliminary phase II results of the salicylate rich formula CV247 in patients with malignant disease. Thomas R, Godward S, Williams M, Wassif W.

BOA Annual Scientific Meeting in association with BASO, Cambridge . September 2002.

 Examining tolerability, quality of life and patient preference of letrozole versus anastrozole in a multicentre, randomised, single blind cross over study. Makris A,  Thomas R,  Bloomfield D, Godward S, Moody M. 25^th Annual San Antonio Breast Cancer Symposium. Breast Cancer Research and Treatment. Vol. 76, 2002, 265.

 Patient Information – patients in clinical trials are more satisfied. R. Thomas, M, Williams. 2005 EJC , Vol. 3, no.2, pp 384 (ab 1341)

 Can we move to a paperless information system? A Deary & R Thomas. 2005 EJC , Vol. 3, no.2, pp 460 (ab 1587).

 Can switching to letrozole in tamoxifen intolerant post menopausal women improve hot flushes, qol and mood? R Thomas, C Marshall, M Williams, L Walker (26^th San Antonio Breast cancer Conference) Dec 2005. Breast Cancer Research and Treatment ab 2067.